Terminal ileal (TI) images are reliable indicators of completeness of colonoscopy 1 . Studies have shown that TI image provide more convincing than caecal images to verify completion of colonoscopy 2 . Acquisitionof TI images after water insufflation (WI) has been found to produce reliable images 3 .We wanted to identify if TI images after WI through the biopsy channel or narrow band images of TI produce more reliable as part of image documentation. Methods 4 images of terminal ileum were captured using Olympus colonoscope ®. They were 1 captured with conventional white light endoscopy (WLE), 1 captured with white light endoscopy + water insufflation (WLEWI), 1 captured with narrow band imaging (NBI) and 1 captured with NBI + water insufflation (NBIWI).
Introduction
Terminal ileal (TI) images are reliable indicators of completeness of colonoscopy 1 . Studies have shown that TI image provide more convincing than caecal images to verify completion of colonoscopy 2 . Acquisitionof TI images after water insufflation (WI) has been found to produce reliable images 3 .We wanted to identify if TI images after WI through the biopsy channel or narrow band images of TI produce more reliable as part of image documentation. Methods 4 images of terminal ileum were captured using Olympus colonoscope ®. They were 1 captured with conventional white light endoscopy (WLE), 1 captured with white light endoscopy + water insufflation (WLEWI), 1 captured with narrow band imaging (NBI) and 1 captured with NBI + water insufflation (NBIWI).
Without informing that these were TI images, the 4 terminal images were sent to endoscopists by email along with an invitation to participate in a survey using survey monkey® portal. Using the survey the respondents marked each image as follows: not terminal ileum = 1, may be terminal ileum = 2, most likely terminal ileum = 3, definitely terminal ileum = 4. Results 36 endoscopists completed our survey. 49% were gastroenterology Specialist registrar, 40% were consultant gastroenterologists and 11% were colorectal surgeons. Most of the respondents (n = 31) were from the UK, 4 were from the United States and 1 was from the rest of the Europe.
19.4% (n = 7) of respondents had colonoscopy experience of 1-2 years, 30.6% (n = 11) had colonoscopy experience of 3-5 years, 19.4% (n = 7) had colonoscopy experience of 5-9 years 30.6% (n = 11) had colonoscopy experience of more than 10 years.
Responses in Table 1 :
Abstract PWE-067 Introduction Colonoscopy is generally perceived as being a painful procedure. Nonetheless, pain is a rather subjective experience for individuals and can be multifactorial. The aim of this study was to identify the predictors of pain during colonoscopy. Methods 1824 consecutive colonoscopies performed in 2010 were identified. Data was retrospectively collected on gender, patients' medical co-morbidities, type and effectiveness of bowel preparation, medication used during the procedure, endoscopist's performance and endoscopic findings such as presence of diverticular disease. Logistic regression analysis was used to identify independent predictors of pain during the procedure. 
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Results Male patients were found to be less likely to develop pain during colonoscopy (odds ratio (OR) 0.43, 95% CI 0.35-0.53, p < 0.001). Those who had any malignancy in the past (OR 0.69, 95% CI 0.49-0.97, p = 0.02) and previous abdominal surgery (OR 0.63, 95% CI 0.47-0.84, p = 0.02) were less prone to having pain. Better bowel preparation improved the comfort of the procedure (OR 0.67, 95% CI 0.54-0.85, p = 0.001) however those who used Moviprep as bowel preparation were more likely to complain of pain (OR 1.83, 95% CI 1.34-2.49, p < 0.001). Higher dose of pethidine requirement was found to be associated with increase likelihood of reporting pain (OR 1.03, 95% CI 1.02-1.04, p < 0.001) but no association was found with the use of midazolam or buscopan. High performance endoscopists were found to cause less pain (OR 0.35, 95% CI 0.27-0.46, p = p < 0.001). The presence of diverticular disease showed a strong trend towards increasing probability of pain although it did not reach statistical significance (OR1.4, 95% CI 1.1-1.8, p = 0.07). Age and medical co-morbidities like rheumatological and neurological problems did not have any significant association. Conclusion Likelihood of having abdominal pain during colonoscopy was found to be associated with being female, having poor bowel preparation and the procedure being performed by non-high performing endoscopists. Patients with past history of malignancy were also noted to have less tendency of having pain. The association of higher dose of pethidine and reported pain was likely to reflect the need of larger doses in such situation. Interestingly, history of previous abdominal surgery did not increase the likelihood of reporting pain and in fact had the opposite effect. The reason for why patients who had Moviprep as bowel preparation were more likely to complain of pain is unknown and this may need to be explored in future studies. Disclosure of Interest None Declared. We aimed to trial this device in a cohort of patients to assess efficacy. Methods We implanted the EndoBarrier bypass sleeve into 57 patients from January 2011 to December 2012. The EndoBarrier is an impermeable fluoropolymer sleeve that is reversibly fixated to the duodenal bulb and extends 80cm into the small bowel, usually terminating in the proximal jejunum. It is implanted in the GI tract endoscopically to create a barrier between food and the wall of the intestine and to delay the mixing of digestive enzymes with food. It alters the activation of hormonal signals that originate in the intestine, thus mimicking the effects of a Roux-en-Y gastric bypass procedure without surgery.
THE DUODENAL-JEJUNAL BYPASS SLEEVE (ENDOBARRIER GASTROINTESTINAL LINER) FOR WEIGHT LOSS AND TREATMENT OF TYPE II DIABETES
Results Results showed weight loss in all patients, as well as lowering of blood sugar levels. Only 1 early device removal (due migration) occurred. There were no major postoperative side effects. Conclusion Results confirm that the device reduces blood sugar levels and triggers weight loss. This non-permanent device implanted and removed endoscopically, controlled blood sugar and weight loss without the trauma of surgery. Clinical trials to date, involving more than 300 patients, have demonstrated significant weight loss and diabetes improvement with the Endobarrier.
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However, since this is a new procedure and due to the lack of data, it is not yet known if weight loss and diabetes benefits will persist. Disclosure of Interest None Declared. Introduction Despite increasing awareness of the potential hazards of endoscopic sedation, complications from sedation remain a major concern. Serious harm or death resulting from sedation overdose is now a Department of Health 'never event' 5-14mg ). Mean dose of opioid (as pethidine equivalent) was 47.9mg (range 12.5-150mg). Higher than recommended doses of midazolam (5mg) or opioid (pethidine equivalent 50mg) were administered in 7.4% and 6.7% of reversal events, respectively. Endoscopic Retrograde Cholangiopancreatography (ERCP) was most associated with sedation reversal (1%). Mean dose of midazolam varied by procedure type and was highest for ERCP (5.1±2.9mg) and lowest for flexible sigmoidoscopy (1.7±0.6mg; p < 0.01). Mean dose of pethidine or opioid equivalent was highest for ERCP (78±38.7mg) and lowest for colonoscopy (33±13.4mg; p < 0.01). Sedation reversal was positively associated with increasing patient ASA grade (p < 0.05). Conclusion Despite the emergence of national and local guidelines, aimed at safe sedation practise, there was no decline in our Trust's rate of sedation reversals over the last 12 years. Furthermore, the findings suggest there is a subgroup of patients, and a subset of endoscopic procedures, which still carry a significant risk of oversedation requiring reversal. This may support the growing interest in alternative sedation strategies for prolonged therapeutic endoscopic procedures such as ERCP. Disclosure of Interest None Declared.
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